Skip to main content

Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer

Objective

IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA).

Palliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (≤10 sites, WHO 0-1: “oligo+”) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC.

IMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance
  • /medical and health sciences/clinical medicine/cancer

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITEIT MAASTRICHT
Address
Minderbroedersberg 4-6
6200 MD Maastricht
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 218 818,75

Participants (16)

DANMARKS TEKNISKE UNIVERSITET
Denmark
EU contribution
€ 774 120
Address
Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS MAASTRICHT
Netherlands
EU contribution
€ 181 675
Address
P Debyelaan 25
6229 HX Maastricht
Activity type
Research Organisations
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 165 050
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
UNIVERSITA CATTOLICA DEL SACRO CUORE
Italy
EU contribution
€ 115 175
Address
Largo Gemelli 1
20123 Milano
Activity type
Higher or Secondary Education Establishments
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 115 175
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
UNIVERSITEIT GENT
Belgium
EU contribution
€ 115 175
Address
Sint Pietersnieuwstraat 25
9000 Gent
Activity type
Higher or Secondary Education Establishments
CLINIQUES UNIVERSITAIRES SAINT-LUC
Belgium
EU contribution
€ 115 175
Address
Avenue Hippocrate 10
1200 Bruxelles
Activity type
Research Organisations
CENTRE OSCAR LAMBRET
France
EU contribution
€ 115 175
Address
Rue Frederic Combemale 3
59020 Lille
Activity type
Other
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 165 050
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 115 175
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITAET DRESDEN
Germany
EU contribution
€ 115 175
Address
Helmholtzstrasse 10
01069 Dresden
Activity type
Higher or Secondary Education Establishments
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 115 175
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
PHILOGEN SPA
Italy
EU contribution
€ 726 250
Address
Piazza La Lizza 7
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HEALTH INNOVATION VENTURES BV
Netherlands
EU contribution
€ 740 500
Address
Oxfordlaan 55 Biopartner Gebouw
6229 EV Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PT THERAGNOSTIC BV

Participation ended

Netherlands
EU contribution
€ 6 250
Address
Oxfordlaan 55 Biopartner Building
6229 EV Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN CANCER PATIENT COALITION
Belgium
EU contribution
€ 95 062,50
Address
Rue Montoyer 40
1000 Bruxelles
Activity type
Other